MINNEAPOLIS, Feb. 6, 2014 /PRNewswire/ -- Uroplasty, Inc.
(NASDAQ: UPI) a medical device company that develops, manufactures
and markets innovative proprietary products for the treatment of
voiding dysfunctions, today announced that Independence Blue Cross
(IBC) has written a positive coverage policy for Percutaneous
Tibial Nerve Stimulation (PTNS) delivered via Uroplasty's
Urgent® PC Neuromodulation System for treatment of
overactive bladder (OAB) and associated symptoms of urinary
urgency, urinary frequency and urge incontinence. IBC covers
2.2 million lives and this decision provides patient coverage for
ongoing treatments for up to two years. IBC is the leading health
insurer in southeastern Pennsylvania, serving Bucks, Chester, Delaware, Montgomery, and Philadelphia counties.
"This positive coverage decision is another example of the
success we are achieving in working directly with payers to
demonstrate the cost effectiveness and the clinical benefits of
Urgent PC in treating patients with OAB," said Nancy Kolb, Vice President of Healthcare Policy
and Reimbursement. "We now have approximately 110 million
lives covered by private payers and 40 million Medicare
beneficiaries with access to Urgent PC therapy following this
decision by IBC."
The policy is available on the Independence BC site at
www.ibx.com.
About Overactive Bladder
Overactive bladder (OAB) is
a chronic condition that affects approximately 42 million US
adults. The symptoms include urinary urgency, frequency and
urge incontinence. The Urgent PC Neuromodulation System is
the only commercially available FDA cleared device that delivers
Percutaneous Tibial Nerve Stimulation (PTNS) therapy.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered
in Minnetonka, Minnesota, with
wholly-owned subsidiaries in The
Netherlands and the United
Kingdom is a global medical device company that develops,
manufactures and markets innovative proprietary products for the
treatment of voiding dysfunctions. Our focus is the continued
commercialization of our Urgent® PC Neuromodulation System, the
only commercially available FDA-cleared system that delivers
percutaneous tibial nerve stimulation (PTNS) for the office-based
treatment of overactive bladder and associated symptoms of urgency,
frequency and urge incontinence. We also offer Macroplastique®, an
injectable urethral bulking agent for the treatment of adult female
stress urinary incontinence primarily due to intrinsic sphincter
deficiency. For more information on the company and its products,
please visit Uroplasty, Inc. at www.uroplasty.com.
For Further Information:
Uroplasty, Inc.
Brett Reynolds, SVP and CFO
952.426.6152
EVC Group
Leigh Salvo (Investors)/Janine McCargo (Business Media)
415.568.9349/646.688.0245
SOURCE Uroplasty, Inc.